$ATYR
aTyr Pharma Inc

2019 Q3 Form 10-Q Financial Statement

#000156459019032173 Filed on August 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2
Revenue $184.0K $94.00K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.880M $2.420M $3.480M
YoY Change -24.19% -30.46% -0.29%
% of Gross Profit
Research & Development $3.799M $3.314M $6.484M
YoY Change -9.59% -48.89% -22.99%
% of Gross Profit
Depreciation & Amortization $160.0K $150.0K $200.0K
YoY Change -15.79% -25.0% 17.65%
% of Gross Profit
Operating Expenses $5.682M $5.735M $9.960M
YoY Change -14.9% -42.42% -16.35%
Operating Profit -$5.498M -$5.641M
YoY Change -17.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$147.0K -$207.0K -$452.0K
YoY Change -66.36% -54.2% 95.67%
Pretax Income -$5.650M -$5.850M -$10.41M
YoY Change -20.53% -43.8% -14.25%
Income Tax
% Of Pretax Income
Net Earnings -$5.645M -$5.848M -$10.41M
YoY Change -20.65% -43.83% -14.22%
Net Earnings / Revenue -3067.93% -6221.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.468M -$1.806M -$4.887M
COMMON SHARES
Basic Shares Outstanding 3.890M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.06M $42.40M $64.30M
YoY Change -31.98% -34.06% 12.41%
Cash & Equivalents $17.34M $14.51M $19.27M
Short-Term Investments $20.72M $27.89M $45.10M
Other Short-Term Assets $1.100M $1.500M $1.700M
YoY Change -35.29% -11.76% -10.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.14M $43.87M $66.00M
YoY Change -32.09% -33.53% 11.68%
LONG-TERM ASSETS
Property, Plant & Equipment $1.386M $1.512M $2.200M
YoY Change -30.7% -31.27% 10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $221.0K $215.0K $100.0K
YoY Change 121.0% 115.0% -75.0%
Total Long-Term Assets $4.601M $4.891M $2.300M
YoY Change 113.5% 112.65% -4.17%
TOTAL ASSETS
Total Short-Term Assets $39.14M $43.87M $66.00M
Total Long-Term Assets $4.601M $4.891M $2.300M
Total Assets $43.75M $48.76M $68.30M
YoY Change -26.85% -28.61% 11.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.324M $664.0K $800.0K
YoY Change 120.67% -17.0% -70.37%
Accrued Expenses $1.579M $1.582M $2.500M
YoY Change -34.21% -36.72% -40.48%
Deferred Revenue $352.0K $536.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.844M $7.817M $7.700M
YoY Change 1.87% 1.52% 176.38%
Total Short-Term Liabilities $11.83M $11.30M $11.10M
YoY Change 10.54% 1.84% 15.04%
LONG-TERM LIABILITIES
Long-Term Debt $2.742M $4.600M $11.80M
YoY Change -72.85% -61.02% 0.07%
Other Long-Term Liabilities $2.400M $2.600M
YoY Change
Total Long-Term Liabilities $2.742M $4.600M $11.80M
YoY Change -72.85% -61.02% 0.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.83M $11.30M $11.10M
Total Long-Term Liabilities $2.742M $4.600M $11.80M
Total Liabilities $14.57M $15.90M $22.90M
YoY Change -29.95% -30.55% 6.8%
SHAREHOLDERS EQUITY
Retained Earnings -$316.3M -$310.7M
YoY Change 8.19%
Common Stock $50.00K $49.00K
YoY Change 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.74M $30.23M $45.38M
YoY Change
Total Liabilities & Shareholders Equity $43.75M $48.76M $68.30M
YoY Change -26.82% -28.61% 11.11%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income -$5.645M -$5.848M -$10.41M
YoY Change -20.65% -43.83% -14.22%
Depreciation, Depletion And Amortization $160.0K $150.0K $200.0K
YoY Change -15.79% -25.0% 17.65%
Cash From Operating Activities -$4.260M -$4.820M -$9.180M
YoY Change -34.06% -47.49% -0.97%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00 -$50.00K
YoY Change -25.0% -100.0% -88.89%
Acquisitions
YoY Change
Other Investing Activities $7.230M $2.300M $7.220M
YoY Change -65.17% -68.14% -38.29%
Cash From Investing Activities $7.210M $2.300M $7.170M
YoY Change -65.22% -67.92% -36.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -120.0K 4.070M -640.0K
YoY Change -94.0% -735.94% -112.7%
NET CHANGE
Cash From Operating Activities -4.260M -4.820M -9.180M
Cash From Investing Activities 7.210M 2.300M 7.170M
Cash From Financing Activities -120.0K 4.070M -640.0K
Net Change In Cash 2.830M 1.550M -2.650M
YoY Change -76.94% -158.49% -137.75%
FREE CASH FLOW
Cash From Operating Activities -$4.260M -$4.820M -$9.180M
Capital Expenditures -$30.00K $0.00 -$50.00K
Free Cash Flow -$4.230M -$4.820M -$9.130M
YoY Change -34.11% -47.21% 3.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Operating Expenses
OperatingExpenses
20180000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11518000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-207000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-10412000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5848000
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3890185
dei Entity File Number
EntityFileNumber
001-37378
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
203435077
dei Entity Address Address Line1
EntityAddressAddressLine1
3545 John Hopkins Court
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite #250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
731-8389
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14507000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22962000
CY2019Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
27891000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
26583000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1473000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1258000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
43871000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
50803000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1512000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1853000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3164000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
215000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2019Q2 us-gaap Assets
Assets
48762000
CY2018Q4 us-gaap Assets
Assets
52746000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
664000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1040000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1582000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2026000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
536000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
705000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
7817000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7767000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11304000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10833000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2632000
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4600000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8263000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
49000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
340893000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
332378000
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-32000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310686000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20180000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-467000
us-gaap Net Income Loss
NetIncomeLoss
-11985000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-298701000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1780000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
361000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-198000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-816000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3314000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6484000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2421000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-899000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.89
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2132113
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35000
CY2019Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1381000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
571000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
30226000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
33650000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48762000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52746000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6137000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
29485000
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8000
CY2019Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1146000
CY2019Q2 life Stock Issued During Period Value At Registered Direct Offering
StockIssuedDuringPeriodValueAtRegisteredDirectOffering
4918000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
509000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
64245000
CY2018Q1 life Issuance Of Common Stock Upon Exercise Of Options And Release Of Restricted Stock Units
IssuanceOfCommonStockUponExerciseOfOptionsAndReleaseOfRestrictedStockUnits
8000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
928000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-10667000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
54498000
CY2018Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
28000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1211000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19764000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
549000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
30080000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
23375000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
29000000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
45376000
us-gaap Profit Loss
ProfitLoss
-11985000
us-gaap Profit Loss
ProfitLoss
-21079000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
324000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
376000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1080000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2139000
us-gaap Accretion Expense
AccretionExpense
387000
us-gaap Accretion Expense
AccretionExpense
501000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
200000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
119000
life Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
349000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
536000
life Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-155000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10844000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
42500000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
26000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1064000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18576000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
8000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
28000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
8000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
2527000
life Proceeds From Issuance Of Common Stock Through Registered Direct Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughRegisteredDirectOfferingNetOfOfferingCosts
4918000
us-gaap Repayments Of Debt
RepaymentsOfDebt
4000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
667000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3453000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-631000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8455000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1819000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21091000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19272000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed consolidated financial statements and accompanying notes. The most significant estimates in our condensed consolidated financial statements relate to clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p>
CY2019Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-14
CY2019Q2 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
42400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1476719
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1721882
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1476719
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1721882
us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3500000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3500000
CY2019Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0960
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
35469
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
396736
CY2018Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
600000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.096
CY2017Q2 life Lease Facility
LeaseFacility
24494
CY2018Q3 life Lease Facility
LeaseFacility
20508
CY2018Q3 life Lease Expiration Term
LeaseExpirationTerm
2023-05
CY2018Q3 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2018Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
With the lease amendment, we do not have an option to extend the lease
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
492000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1002000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1031000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1062000
CY2019Q2 life Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
404000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
654000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3337000
CY2019Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2065218
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
356353
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
75852
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.61
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
71.85
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
51.19
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
509000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1211000

Files In Submission

Name View Source Status
0001564590-19-032173-index-headers.html Edgar Link pending
0001564590-19-032173-index.html Edgar Link pending
0001564590-19-032173.txt Edgar Link pending
0001564590-19-032173-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
life-10q_20190630.htm Edgar Link pending
life-20190630.xml Edgar Link completed
life-20190630.xsd Edgar Link pending
life-20190630_cal.xml Edgar Link unprocessable
life-20190630_def.xml Edgar Link unprocessable
life-20190630_lab.xml Edgar Link unprocessable
life-20190630_pre.xml Edgar Link unprocessable
life-ex311_8.htm Edgar Link pending
life-ex312_9.htm Edgar Link pending
life-ex321_6.htm Edgar Link pending
life-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending